Is ADMA Biologics Inc (ADMA) overvalued? · P/E 22, rev $426.5M
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
This page asks whether ADMA Biologics Inc (ADMA) looks expensive on cached numbers — not a short thesis.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ADMA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ADMA stock page for the full model, not this heading.
Not investment advice.